Erectile dysfunction is the inability to maintain a firm erection during sexual activity. It is a sign of a physical or psychological condition. Erectile dysfunction is caused by stress, age, depression, diabetes, Blood pressure issues or an unhealthy lifestyle. Various treatments are available for erectile dysfunction such as drugs, injections, and topical creams. Market players are indulged in research and development activities for developing drugs for effective results with minimum time consumption. Viagra is one of the most used drugs for erectile dysfunction. Many companies are engaged to receive approval from regulatory authorities for generic medicines which drives the growth of erectile dysfunction treatment market. For instance, in December 2017, Teva Pharmaceuticals which is pharmaceutical manufacturer of high quality generic medicines has received the U.S. Food and Drug Administration (U.S.FDA) approval of generic medicine for Viagra and another generic version of Vardenafil was approved by the U.S.FDA in October 2018.Vardenafill is class of medicine called Phosphodiesterase (PDE) inhibitors which helps in increasing the blood flow to penile tissue to cause erection.
Market Dynamics
Market players are engaged in providing advanced treatments for erectile dysfunction for effective and efficient results. This is expected to increase the growth of the global erectile dysfunction treatment market over the forecast period. For instance, an article published on January 25, 2019 by the National Center for Biotechnology Information (NCBI) states that advanced treatments are available for erectile dysfunction treatment such as penile prosthesis, vacuum-assisted erectile, intraurethral suppository, along with novel therapies such as stem cell therapy, external penile prosthesis, platelet-rich plasma, and penile shockwave therapy, which help to reduce erectile dysfunction in men.
Increasing awareness for the treatment as well as management of erectile dysfunction is expected to increase the growth of the global erectile dysfunction treatment market over the forecast period. For instance, on February 12, 2021, Sexual and Reproductive Health Awareness day was celebrated to raise the awareness for sexual health awareness. This program was started by Canadian government, and it has since spread around the globe. This program aims to provide information to socially and educationally backward population to avoid the serious issues cause due to erectile dysfunction as the prevalence of erectile dysfunction is increasing globally.
This programme was started by the Canadian government, and it has since spread around the world.
Key features of the study:
- This report provides an in-depth analysis of global erectile dysfunction treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global erectile dysfunction treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Boston Scientific, Mylan Pharmaceuticals Inc., Cipla Ltd., Pfizer Inc, Coloplast CORP, Eli Lily & Co, Gust Inc., Altera, Promedon , Dr. Reddys Laboratories Ltd., Zephyr Surgical Implants, Pos-T-Vac Inc., Bayer Pharma AG, Reflexonic Llc., Dong-A Pharmaceutical Co. Ltd., Owen Mumford Ltd., Vacurect Manufacturing Ltd., and
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global erectile dysfunction treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global erectile dysfunction treatment market
Detailed Segmentation:
- Global Erectile Dysfunction Treatment Market, By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- Global Erectile Dysfunction Treatment Market, By Route of Administration:
- Oral drugs
- Injections
- Topical application
- Global Erectile Dysfunction Treatment Market, By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- Global Erectile Dysfunction Treatment Market, By Region:
- North America
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- Middle East
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drugs:
- Sildenafil (Viagra)
- Vardenafil (Levitra Staxyn)
- Tadalafil (Cialis)
- Avanafil (Stendra)
- Udenafil (Zydena)
- Others
- By Route of Administration:
- Oral drugs
- Injections
- Topical application
- By Distribution Channel:
- Hospitals Pharmacies
- Offline Pharmacies
- Online Pharmacies
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Boston Scientific *
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Mylan Pharmaceuticals Inc.
- Cipla Ltd
- Pfizer Inc.
- Coloplast CORP
- Eli Lily & Co,
- Gust Inc.
- Altera
- Promedon
- Reddys Laboratories Ltd
- Zephyr Surgical Implants
- Pos-T-Vac Inc.
- Bayer Pharma AG
- Reflexonic Llc.
- Dong-A Pharmaceutical Co. Ltd.
- Owen Mumford Ltd
- Vacurect Manufacturing Ltd
- Silimed
“*” marked represents similar segmentation in other categories in the respective section
